 |
|
COMMENTS AND OPINIONS
Notice of Failure to Disclose Financial Interest: "A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials" (Arch Neurol. 2007;64[9]:1323-1329)
John Harrison, CPsychol, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
A matter has come to my attention that I would appreciate having the opportunity of addressing through the pages of the Archives. The issue relates to our article1 on the neuropsychological test battery (NTB) published in September 2007 and my consulting relationship with Elan Pharmaceuticals and Wyeth Research. Let me begin by clarifying my financial position regarding the NTB:
- The NTB is a nonproprietary clinical tool. It is not now, nor has ever been, owned by me or any organization in which I have held a financial interest.
- I have received no payment from the authors or owners of the NTB tests for recommending their inclusion in any study.
Additionally, although in the course of my activities I have received consultancy payments from a number of drug development sponsors, I have never held or traded stock in a client company, including Elan Pharmaceuticals and Wyeth . . . [Full Text of this Article] AUTHOR INFORMATION
RELATED ARTICLE
A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials
John Harrison, Sonia L. Minassian, Lisa Jenkins, Ronald S. Black, Martin Koller, and Michael Grundman
Arch Neurol. 2007;64(9):1323-1329.
ABSTRACT
| FULL TEXT
RELATED LETTER
Unreported Financial Disclosures
Roger N. Rosenberg
Arch Neurol. 2008;65(7):992.
EXTRACT
| FULL TEXT
|
